Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug
Physician's Weekly
JUNE 18, 2025
Verve is developing a new class of gene-editing drugs that could be given just once to treat chronic conditions. More information Learn more about Verve Therapeutics. Verve’s board has agreed to the sale and recommends shareholders support the decision. The deal is expected to close by the third quarter of this year.
Let's personalize your content